Lv3
280 积分 2023-01-29 加入
A first-in-class oral clinical candidate targeting MLLT1 and 3 degradation for the treatment of advanced AML and ALL including menin inhibitor resistant / refractory disease
13天前
已关闭
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
21天前
已完结
Betting on β-catenin inhibitors in oncology
1个月前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
1个月前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
1个月前
已完结
Regulatory, product development, resources, and financial challenges associated with creating and commercializing combination products
5个月前
已关闭
Moving toward Meaningful Standards for Preclinical Performance Testing of Medical Devices and Combination Products with Antimicrobial Effects
5个月前
已完结
Moving toward Meaningful Standards for Preclinical Performance Testing of Medical Devices and Combination Products with Antimicrobial Effects
5个月前
已关闭
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
6个月前
已完结
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
6个月前
已完结
皖公网安备34019202002308
